Vaccine for preventing and treating Merkel cell carcinoma
AssigneeAdvaccine (Suzhou) Biopharmaceuticals Co. Ltd.
InventorsYue He, Gan Zhao, Lunan Zhang, Xin Cheng, Qingling Yu
Life of this patent
Estimating the term…
Abstract
The present invention provides a novel vaccine for preventing and treating Merkel cell carcinoma. The present invention constructs a therapeutic vaccine based on a Merkel cell polyomavirus capsid protein VP1 by taking the Merkel cell polyomavirus capsid protein VP1 as an antigen, in combination with a TLR agonist. The present invention effectively solves the problem of prevention and treatment of the Merkel cell carcinoma and has great application value and application prospects.
Claims20
A vaccine composition against Merkel cell carcinoma comprising:
- (a) Merkel cell polyomavirus capsid protein VP1 or a nucleic acid comprising a nucleotide sequence encoding the Merkel cell polyomavirus capsid protein VP1;
- and (b) a TLR agonist comprising one or more of CpG, R848, and MPL;
- wherein the nucleotide sequence encoding the Merkel cell polyomavirus capsid protein VP1 is 71.9%-74.7% identical to SEQ ID No. 6.
A nucleic acid encoding Merkel cell polyomavirus capsid protein VP1, wherein the nucleic acid comprising a nucleotide sequence 71.9%-74.7% identical to SEQ ID No. 6;
- and wherein the nucleotide sequence encodes the VP1.
Dependencies are inferred from the claim text.